6 Top Gainers In Healthcare Sector (MLNT, ARCT, MYOS...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Melinta Therapeutics Inc. (MLNT)

Gained 223.74% to close Wednesday's (June 19) trading at $6.41.

News: The FDA has accepted the Company's supplemental New Drug Application for BAXDELA, seeking to include adult patients with community-acquired bacterial pneumonia, for priority review.

The regulatory decision is set for October 24, 2019.

BAXDELA was approved by the FDA in 2017 for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

2. Diversicare Healthcare Services Inc. (DVCR)

Diversicare is a premier provider of long-term care services.

Gained 75.19% to close Wednesday's trading at $4.73.

News: No news

Recent event:

On May 2, 2019, the Company reported financial results for its first quarter ended March 31, 2019.

Net loss from continuing operations was $3.3 million, or $0.52 per share in the first quarter of 2019, compared to a net loss from continuing operations of $0.1 million, or $0.01 per share in the first quarter of 2018. Total revenue in the first quarter of 2019 decreased to $134.4 million from $141.3 million in the year-ago quarter.

3. AquaBounty Technologies Inc. (AQB)

AquaBounty is a biotechnology company focused on enhancing productivity in the aquaculture market.

Gained 39.91% to close Wednesday's trading at $3.12.

News: No news

Recent event:

The net loss for the recent first quarter was $2.76 million or $0.18 per share compared to a net loss of $2.45 million or $0.21 per share in the year-ago quarter. Product revenue in the first quarter of 2019 surged to $97 thousand from $19 thousand in the year-ago quarter.

4. Arcturus Therapeutics Ltd. (ARCT)

Gained 36.68% to close Wednesday's trading at $7.90.

News: Arcturus and Ultragenyx Pharmaceutical, Inc. (RARE) have expanded their collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.

Ultragenyx has made $30 million of upfront payments to Arcturus, including $6 million cash for collaboration agreement amendment and a $24 million equity investment at $10 per share.

Ultragenyx has an option to purchase an additional 600,000 shares of Arcturus' common stock at $16 per share.

Ultragenyx will become Arcturus' largest shareholder with Karah Parschauer, General Counsel of Ultragenyx, joining Arcturus' Board of Directors and Emil D. Kakkis, Chief Executive Officer and President of Ultragenyx, joining as an Arcturus Board Observer.

5. MYOS RENS Technology Inc. (MYOS)

MYOS is a nutrition company and the owner of Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle.

Gained 26.87% to close Wednesday's trading at $1.70.

News: The Company announced positive top-line results from a randomized, double-blind, placebo-controlled study that was conducted at the University of California, Berkeley and the University of Arkansas for Medical Sciences evaluating the impact of Fortetropin on the rate of muscle protein synthesis in older men and women (60-75 years of age).

According to the study results, for subjects who received Fortetropin, the average fractional synthetic rate (FSR) in several gene ontologies were significantly higher compared to the placebo group. The proportion of proteins with an increased FSR in the Fortetropin group relative to the placebo group was found to be statistically significant.

6. Armata Pharmaceuticals, Inc. (ARMP)

Armata is a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.

Gained 17.48% to close Wednesday's trading at $3.36.

News: The Company is slated to host a Key Opinion Leader (KOL) meeting on phage-based therapeutics for the treatment of antimicrobial-resistant infections on June 26 from 12:00 - 1:30 PM EDT in New York City.